Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Are The Market Size Estimates For The Intermittent Claudication Market?

The market size of intermittent claudication has seen robust growth in the past few years. It is projected to expand from $12.81 billion in 2024 to $13.51 billion in 2025, with a compound annual growth rate (CAGR) of 5.5%. The significant growth during the historical period can be linked to the increase in peripheral artery disease, heightened awareness about vascular diseases, rise in the elderly population, improved diagnosis rates, and increased spending on healthcare.

The market size for intermittent claudication is predicted to experience considerable growth in the coming years. By 2029, it will expand to $16.99 billion, with a Compound Annual Growth Rate (CAGR) of 5.9%. This growth during the projected period can be attributed to factors such as the rise in diabetes cases, increasing obesity rates, growing occurrences of cardiovascular diseases, increased consumption of alcohol and tobacco, and heightened expenditure in healthcare. The forecast period will also see major trends such as the advancement in peripheral arterial disease diagnostics, integration of wearable tech devices, personalized medicine advancements, a shift towards the use of drug-eluting stents, and progress in stem cell therapy.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22021&type=smp

What Drivers Are Accelerating Expansion Of The Intermittent Claudication Market?

The rise in peripheral artery disease (PAD) cases is anticipated to stimulate the expansion of the intermittent claudication market moving forward. PAD is a circulatory problem in which the constriction of the arteries reduces blood circulation to the limbs, resulting in pain, numbness, and potential complications. The surge in PAD cases can be attributed to an aging population, diabetes, smoking, hypertension, obesity, and sedentary behavior. PAD leads to intermittent claudication by limiting blood flow to the leg muscles while working out, which results in pain and cramping due to a lack of oxygen. For instance, in June 2023, the American Heart Association Journals, a peer-reviewed open-access scientific journal based in the U.S, reported that PAD affects 7-12 million people in the U.S and 200 million worldwide. Hence, the surge in PAD cases is propelling the growth of the intermittent claudication market.

What Are The Key Segment Trends Observed In The Intermittent Claudication Market?

The intermittent claudicationmarket covered in this report is segmented –

1) By Type: Medication Therapies; Revascularization

2) By Route Of Administration: Parenteral Route; Oral Route; Other Routes Of Administration

3) By Application: Hospitals; Clinics; Home Healthcare; Other Applications

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Subsegments:

1) By Medication Therapies: Antiplatelet Agents; Vasodilators; Phosphodiesterase Inhibitors; Cilostazol; Pentoxifylline

2) By Revascularization: Angioplasty; Stenting; Bypass Surgery; Endarterectomy

What Strategic Shifts And Innovations Are Influencing The Intermittent Claudication Market?

In the intermittent claudication market, major companies are focusing on advanced medication therapies, such as RIPK1 inhibitors, to enhance treatment outcomes for patients suffering from peripheral artery disease (PAD) with intermittent claudication, aiming to improve blood flow, reduce inflammation, and prevent disease progression. RIPK1 inhibitors refer to targeted drugs that block RIPK1 kinase activity, reducing inflammation and cell death. For instance, in August 2022, GenFleet, a China-based biotechnology company, received U.S. Food and Drug Administration (FDA) approval for a Phase II clinical trial of GFH312, an innovative therapy for peripheral artery disease (PAD) with intermittent claudication (IC). This randomized, double-blinded, placebo-controlled study will be conducted at 15 research centers. GFH312 is a RIPK1 inhibitor that has shown promise in preclinical studies by curbing the inflammatory response in animal models.

Who Are The Major Stakeholders Operating In The Intermittent Claudication Market?

Major companies operating in the intermittent claudication market are Pfizer Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Merck KGaA, Teva Pharmaceutical, Otsuka Pharmaceutical Co. Ltd., Sanofi S.A., Bayer AG, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories, Pipelinepharma, Pharmaoffer, Alkem Laboratories, LGM Pharma, Aastrid Life Sciences Pvt. Ltd., Manus Aktteva Biopharma LLP, Enomark Pharma, Pharmacompass.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/intermittent-claudication-global-market-report

What Regional Factors Are Accelerating Growth In The Intermittent Claudication Market?

North America was the largest region in the intermittent claudication market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intermittent claudication market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=22021&type=smp

Browse Through More Reports Similar to the Global Intermittent Claudication Market 2025, By The Business Research Company

Intermittent Catheters Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/intermittent-catheters-global-market-report

Intermittent Pneumatic Compression Ipc Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/intermittent-pneumatic-compression-ipc-devices-global-market-report

Coronary Artery Disease Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/coronary-artery-disease-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model